DB 1419
Alternative Names: DB-1419Latest Information Update: 08 Oct 2024
At a glance
- Originator Duality Biologics
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 03 Sep 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Australia (IV) (NCT06554795)
- 23 Aug 2024 Duality Biologics plans a phase I/II trial for Solid tumours (Late stage disease) in China, USA and Australia (IV) In August 2024 (NCT06554795)
- 23 Aug 2024 Preclinical trials in Solid tumours in China (Parenteral) before August 2024 (Duality Biologics pipeline, August 2024)